Form 4: Vertex Chairman Acquires 9,012 Performance Shares

Vertex Pharmaceuticals' Executive Chairman, Jeffrey M. Leiden, acquired 9,012 shares of common stock through the vesting of performance-based awards.

Summary

• Jeffrey M. Leiden, Executive Chairman and Director of Vertex Pharmaceuticals Inc. (VRTX), acquired 9,012 shares of common stock.
• The acquisition occurred on January 22, 2026, and represents earned performance shares from a performance stock unit (PSU) award granted on February 12, 2025.
• The company's management development and compensation committee certified the attainment of performance goals on January 22, 2026.
• The acquired shares will officially vest on February 24, 2026.
• Following this transaction, Mr. Leiden directly beneficially owns 33,039 shares of common stock and indirectly owns 440 shares through a 401(k) plan.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The acquisition of shares by a key executive, even through vesting, signals the achievement of performance targets and aligns management's interests with shareholders. It's not a direct market purchase, which would typically carry a higher sentiment score, but it's still a positive indicator of internal performance.

Positives

• The Executive Chairman's acquisition of 9,012 shares, albeit through vesting, indicates successful achievement of performance goals, reflecting positively on company performance.
• Insider ownership, particularly by a high-ranking executive, can signal confidence in the company's future prospects to the market.

Future Outlook

The shares acquired are scheduled to vest on February 24, 2026, indicating a future milestone for the performance-based compensation.

Industry Context

Insider transactions, such as the vesting of performance-based equity awards, are common in the pharmaceutical industry as a component of executive compensation, aligning management's interests with shareholder value creation. The successful attainment of performance goals leading to such vesting can be viewed as a positive indicator of operational execution within the competitive biotech and pharma landscape.

Stakeholder Impact

• Shareholders: May view the vesting of performance shares to the Executive Chairman as a positive signal regarding the company's performance and management's alignment with shareholder interests.
• Employees: The successful achievement of performance goals leading to executive compensation vesting could reinforce confidence in the company's strategic direction and leadership.

Next Steps

• The 9,012 performance shares are scheduled to officially vest on February 24, 2026.

Key Dates

Keywords

Vertex Pharmaceuticals, VRTX, Jeffrey M. Leiden, Insider Trading, Form 4, Stock Acquisition, Performance Shares, Executive Compensation